

Aalto Bio Reagents

BIOSYNTH[®] GROUP

Monkeypox Virus




Aalto Bio Reagents Launches New Monkeypox Virus B21R-BSA Conjugate Peptides for Diagnostic Testing

As of 2nd October 2022, approximately 70,000 cases have been reported from 106 countries this year according to the World Health Organisation (WHO), prompting them to declare the outbreak “a public health emergency of international concern”. Aalto Bio Reagents Ltd. has developed new peptides for Monkeypox virus (MPV) B21R-A and B21R-B - BSA conjugate to assist assay manufacturers with production of critical serology assays.

Product	Code
Monkeypox virus B21R-A – BSA conjugate, Zaire strain	DL 7025
Monkeypox virus B21R-B – BSA conjugate, Zaire strain	DL 7031

MPV belongs to the Orthopoxvirus genus of the Poxviridae family, which is the same genus as variola virus (the cause of smallpox). Transmission occurs through close contact with skin lesions of an infected person, respiratory secretions and contact with infected surfaces. It is generally a self-limiting disease and treatment for most people is aimed at relieving symptoms. It is characterised by a fever, swollen lymph nodes, fatigue, headache and a painful rash that is often mistaken for chickenpox, making diagnosis difficult on clinical symptoms alone.



Orthopoxviruses have highly conserved genomes, which can lead to significant antibody cross-reactivity among its members. The development of a standard antibody test for MPV is complicated by cross-reactive immune responses induced by vaccinia, the virus used in smallpox vaccines. Aalto Bio's new MPV peptides contain the surface glycoprotein B21R and this region contains important antibody targets as well as several key immunodominant epitopes. When conjugated to a carrier protein like BSA, this has been shown to greatly improve the sensitivity of the assay compared to unconjugated peptide, and enhance stability.

“Following a weary two years of the Covid-19 pandemic, the world is facing a formidable new challenge in the form of MPV. Aalto Bio rose to the challenge and quickly developed these two new peptides when current testing resources were scarce. The world has learnt that an early response and better diagnostics is critical to containing these types of outbreaks” said Philip Noone, CEO of Aalto Bio Reagents.

Please contact info@aaltobioreagents.com to enquire about these products



Veterinary



Purified Human Proteins



Disease State Human Plasmas



Polyclonal Antisera



Antigens



Biospecimens



Mouse Monoclonal Antibodies

Aalto Bio Reagents
BIOSYNTH[®] GROUP

Aalto Bio Reagents Ltd.
Unit A6 Nutgrove Office Park
Dublin D14 DX26
Ireland

Tel: +353-1- 4900685
E: info@aaltobioreagents.com
W: www.aaltobioreagents.com